In 2004, Mylan Laboratories, a US pharmaceutical company, agreed to buy rival King Pharmaceuticals for a substantial premium to its market valuation. Good news for Perry Corp, a hedge fund that had bought 7m shares in King and was set to reap a handsome profit.

But the putative acquisition was not perceived to be quite so good for Mylan; its shares fell on the announcement, putting the deal in jeopardy.